Publications

  1. Motzer, R., Escudier, B., McDermott, D., George, S., Hammers, H., Srinivas, S., Tykodi, S., Sosman, J., Procopio, G., Plimack, E., Castellano, D., Choueiri, T., Gurney, H., Donskov, F., Bono, P., Wagstaff, J., Gauler, T., Ueda, T., Tomita, Y., Schutz, F., Kollmannsberger, C., Larkin, J., Ravaud, A., Simon, J., Xu, L., Waxman, I., Sharma, P. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma New England Journal of Medicine 373 19 1803 1813
  2. Wolchok, J., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J., Cowey, C., Lao, C., Wagstaff, J., Schadendorf, D., Ferrucci, P., Smylie, M., Dummer, R., Hill, A., Hogg, D., Haanen, J., Carlino, M., Bechter, O., Maio, M., Marquez-Rodas, I., Guidoboni, M., McArthur, G., Lebbé, C., Ascierto, P., Long, G., Cebon, J., Sosman, J., Postow, M., Callahan, M., Walker, D., Rollin, L., Bhore, R., Hodi, F., Larkin, J. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma New England Journal of Medicine 377 14 1345 1356
  3. James, N., de Bono, J., Spears, M., Clarke, N., Mason, M., Dearnaley, D., Ritchie, A., Amos, C., Gilson, C., Jones, R., Matheson, D., Millman, R., Attard, G., Chowdhury, S., Cross, W., Gillessen, S., Parker, C., Russell, J., Berthold, D., Brawley, C., Adab, F., Aung, S., Birtle, A., Bowen, J., Brock, S., Chakraborti, P., Ferguson, C., Gale, J., Gray, E., Hingorani, M., Hoskin, P., Lester, J., Malik, Z., McKinna, F., McPhail, N., Money-Kyrle, J., O’Sullivan, J., Parikh, O., Protheroe, A., Robinson, A., Srihari, N., Thomas, C., Wagstaff, J., Wylie, J., Zarkar, A., Parmar, M., Sydes, M. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy New England Journal of Medicine
  4. Hodi, F., Chiarion-Sileni, V., Gonzalez, R., Grob, J., Rutkowski, P., Cowey, C., Lao, C., Schadendorf, D., Wagstaff, J., Dummer, R., Ferrucci, P., Smylie, M., Hill, A., Hogg, D., Marquez-Rodas, I., Jiang, J., Rizzo, J., Larkin, J., Wolchok, J. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial The Lancet Oncology 19 11 1480 1492
  5. James, N., Sydes, M., Clarke, N., Mason, M., Dearnaley, D., Spears, M., Ritchie, A., Parker, C., Russell, J., Attard, G., de Bono, J., Cross, W., Jones, R., Thalmann, G., Amos, C., Matheson, D., Millman, R., Alzouebi, M., Beesley, S., Birtle, A., Brock, S., Cathomas, R., Chakraborti, P., Chowdhury, S., Cook, A., Elliott, T., Gale, J., Gibbs, S., Graham, J., Hetherington, J., Hughes, R., Laing, R., McKinna, F., McLaren, D., O'Sullivan, J., Parikh, O., Peedell, C., Protheroe, A., Robinson, A., Srihari, N., Srinivasan, R., Staffurth, J., Sundar, S., Tolan, S., Tsang, D., Wagstaff, J., Parmar, M. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial The Lancet

See more...